Replacing failed dialysis access devices is costly and, for patients, painful. The prevalence of End Stage Renal Disease in the U.S. means that replacing failed vascular access devices accounts for an astonishingly large amount of annual health care expenses. There is currently no approved product to prevent the kind of internal blood vessel scarring responsible for most chronic access device failure.
A new way to increase access graft patency reduces patient surgeries and access device replacement costs.
To learn more, Contact Us.